FMS-RELATED GENES IN OVARIAN AND ENDOMETRIAL NEOPLASIA

我们已经组装了专门固定和/或冷冻的卵巢， 子宫内膜癌，并已建立，通过定量研究， 原位杂交分析，转录物表达 与FMS相关的探针互补， 在这两个妇科疾病中， 恶性肿瘤。 我们建议进一步扩大这些调查 为了更好地描述这些和其他癌基因在 临床侵袭性卵巢和子宫内膜的发生 肿瘤和表征的分子生物学和细胞 fms-互补转录物和fms-相关 我们临床材料中生长因子受体蛋白产物 在卵巢癌衍生的培养细胞系中， 基因产物似乎在卵巢癌中起重要作用， 子宫内膜癌的发生，可能是一个潜在的目标， “癌基因特异性”药物干预。

We have assembled specially-fixed and/or frozen ovarian and endometrial carcinomas and have established, by quantitative in situ hybridization analyses, that expression of a transcript complementary to a fms-related probe correlates strongly with aggressive clinical behavior in these two gynecologic malignancies. We propose to extend these investigations further to better characterize the role of these and other oncogenes in the genesis of clinically aggressive ovarian and endometrial neoplasms and to characterize the molecular biology and cellular physiology of the fms-complementary transcript and fms-related growth factor receptor protein product in our clinical material and in ovarian carcinoma-derived cultured cell lines, since this gene product appears to play an important role in ovarian and endometrial carcinogenesis and may be a potential target for "oncogene-specific" pharmacologic interventions.